Global Partners SillaJen, Transgene and Lee’s Pharmaceutical Confirm Clinical Development Plan for Pexa-Vec

Enrollment of Phase 3 study in first-line advanced liver cancer expected to begin by mid-2015 – To initiate several additional Phase 1/2 trials during 2014 Marchc 26, 2014 Transgene SA, Lee’s Pharmaceutical and SillaJen today unveiled their late-stage clinical development plan for Pexa-Vec oncolytic immunotherapy. The companies plan to initiate a global Phase 3 study in the first-line treatment of advanced …

Transgene Reports that the Acquisition of Jennerex, Inc. by SillaJen has Closed

Transgene SA announced today the closing of the acquisition of Jennerex, Inc. by SillaJen. March 18, 2014 Philippe Archinard, Chairman and Chief Executive Officer of Transgene, said: “We are very pleased that the acquisition of Jennerex, Inc. by SillaJen has successfully closed in the first quarter of 2014 as planned. Importantly, with our partner for Pexa-Vec now well funded, we will be …

Therapeutic Cancer Vaccines: The failures

Cancer immunotherapy and cancer vaccines were named Science Magazine’s ‘Breakthrough of the Year 2013‘, but whilst the industry continues to be optimistic about the promises of harnessing a patients immune system to treat cancer, it’s hard to ignore the big disappointments that have been recorded in a number of high profile Phase III and II trial failures. Here are just …